Pharmacoeconomic Analysis Of Insulin Human And Insulin Analog In Short-term Intensive Therapy Of First Diagnosed Type 2 Diabetes Patients With Insulin Pump

OBJECTIVESTo to carry out a research on Insulin Aspart and Novolin R with insulin pump in short-term intensive therapy of first diagnosed type 2 diabetes patients in the way of pharmacoeconomics. In order to provide a safe, effectiveand economical alternative for clinic.METHODSThe trial was conducted in a prospective, randomized, and controled design.The first diagnosed type 2 diabetes patients were researched from Janurary 2008 to December 2008 in a comprehensive hospital rated Tertiary-A Hospital.1. Collection of general dataMade a record of age, gender, body mass index(BMI), Glycosylated hemoglobin(HbA1c), fasting blood glucose(FBG), posting 2h blood glucose(PBG2 h) before the short-term intensive therapy.2. MedicationThe type 2 diabetes patients were randomly divided into either of two groups:Insulin Aspart treated group and Novolin R treated group to undergo Minimed 508 insulin pump therapy. The basical dose of insulin was input automatically lasting 24h through linking vessel and embeding pinhead subcutaneouly. The large dose of insulin was input by the staff befor the meal. Finger peripheral blood glucose was measured befor the three meal,2h after the three meal, before retiring.50% of the total insuline per day is administered in both the groups as the basical dose initially, and the large dose of supplemental dose was input befor the three meal.3. Carried out a effectiveness analysis and a cost analysis.To adjust the basical dose and the supplemental dose on the basis of the blood glucose monitoring condition. Finger peripheral blood glucose was measured during the research. The therapic target is controlling FBG≤7.0 mmol/L,PBG2 h≤10.0 mmol/L, lasting 3d stably.The time, clinical manifestation, treatment and recovery of the adverse reaction such as hypoglycemia wrer recorded in detail.To collect the cost during the stage of therapy, and to make a cost analysis.4. Pharmacoeconomic analysisPerform a Pharmacoeconomic analysis making use of Cost-Effective analytical model.RESULTS1. general data102 patients selected were randomly divided into into either of two groups:51 patients in the Insulin Aspart treated group, there are 25females,26 males, the mean age is 51.3±12.9 year old, the mean BMI is (23.9±3.3)kg/m2, the mean HbA1c is (9.0±1.4)%, the mean FBG is (13.2±3.10) mmol/L, and the mean PBG2h is (17.7±3.2) mmol/L; 51 patients in the Novolin R treated group, there are 27females,24 males, the mean age is 50.4±13.6 year old, the mean BMI is (23.8±3.4)kg/m2, the mean HbA1c is (8.9±1.3)%, the mean FBG is (12.7±2.5) mmol/L, and the mean PBG2h is (17.4±3.5) mmol/L.No significant differences in age, BMI, FBG, PBG2h, HbA1c were observed between the two groups (P>0.05). Efficacy and safety evaluation can be carried out.2. effect analystSignificant differences of comparison of the post and front prandial blood glucose were observed within both the two groups after treatment (0.01